Cytosorbents Dirección
Dirección controles de criterios 2/4
El CEO de Cytosorbents' es Phil Chan , nombrado en Jan 2009, tiene una permanencia de 15.25 años. compensación anual total es $1.11M, compuesta por 43.6% salario y 56.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.36% de las acciones de la empresa, por valor de $598.89K. La antigüedad media del equipo directivo y de la junta directiva es de 3.9 años y 9.6 años, respectivamente.
Información clave
Phil Chan
Chief Executive Officer (CEO)
US$1.3m
Compensación total
| Porcentaje del salario del CEO | 36.2% |
| Permanencia del CEO | 15.3yrs |
| Participación del CEO | 1.4% |
| Permanencia media de la dirección | 4yrs |
| Promedio de permanencia en la Junta Directiva | 9.7yrs |
Actualizaciones recientes de la dirección
Recent updates
Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?
Mar 16
Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper
Jan 06Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?
Nov 10Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price
Jul 13Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?
May 16We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate
Mar 08CytoSorbents secures $4.3M contract by U.S. Department of Defense
Oct 06CytoSorbents stock rises on US DoD contract to develop device for universal plasma
Sep 09We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate
Sep 02CytoSorbents gets reimbursement for CytoSorb in Turkey
Aug 23CytoSorbents stock rises 10% as Israel approves coverage for CytoSorb system
Aug 17Cytosorbents GAAP EPS of -$0.25 misses by $0.13, revenue of $8.5M misses by $1.06M
Aug 02We're Not Very Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate
Mar 03Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$1m | US$483k | -US$29m |
| Sep 30 2023 | n/a | n/a | -US$23m |
| Jun 30 2023 | n/a | n/a | -US$26m |
| Mar 31 2023 | n/a | n/a | -US$31m |
| Dec 31 2022 | US$1m | US$483k | -US$33m |
| Sep 30 2022 | n/a | n/a | -US$41m |
| Jun 30 2022 | n/a | n/a | -US$36m |
| Mar 31 2022 | n/a | n/a | -US$29m |
| Dec 31 2021 | US$2m | US$483k | -US$25m |
| Sep 30 2021 | n/a | n/a | -US$16m |
| Jun 30 2021 | n/a | n/a | -US$10m |
| Mar 31 2021 | n/a | n/a | -US$9m |
| Dec 31 2020 | US$1m | US$456k | -US$8m |
| Sep 30 2020 | n/a | n/a | -US$11m |
| Jun 30 2020 | n/a | n/a | -US$17m |
| Mar 31 2020 | n/a | n/a | -US$18m |
| Dec 31 2019 | US$1m | US$438k | -US$19m |
| Sep 30 2019 | n/a | n/a | -US$21m |
| Jun 30 2019 | n/a | n/a | -US$17m |
| Mar 31 2019 | n/a | n/a | -US$19m |
| Dec 31 2018 | US$1m | US$400k | -US$17m |
| Sep 30 2018 | n/a | n/a | -US$15m |
| Jun 30 2018 | n/a | n/a | -US$14m |
| Mar 31 2018 | n/a | n/a | -US$10m |
| Dec 31 2017 | US$828k | US$378k | -US$9m |
Compensación vs. Mercado: La compensación total de Phil($USD1.33M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).
Compensación vs. Ingresos: La compensación de Phil ha aumentado mientras la empresa no es rentable.
CEO
Phil Chan (53 yo)
15.3yrs
Permanencia
US$1,333,402
Compensación
Dr. Phillip P. Chan, M.D., Ph D., is known as Phil has been the Chief Executive Officer at Cytosorbents Corporation since January 2009 and served as its President until May 2020. Dr. Chan serves as a Partn...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 15.3yrs | US$1.33m | 1.36% $ 605.8k | |
| President & COO | 18.8yrs | US$1.11m | 0.52% $ 230.4k | |
| Chief Financial Officer | less than a year | US$816.08k | 0.46% $ 203.2k | |
| Chief Medical Officer | 4yrs | US$1.06m | 0.15% $ 66.5k | |
| Vice President of Investor Relations & Corporate Communications | 2.9yrs | sin datos | sin datos | |
| Executive Vice President of Sales & Marketing | 11.9yrs | sin datos | sin datos | |
| Senior Vice President of Business Development | 1.3yrs | sin datos | sin datos | |
| Senior Vice President of Global Regulatory Affairs | 1.3yrs | sin datos | sin datos | |
| Executive | no data | sin datos | sin datos | |
| Co-Chairman of Cardiac Surgery Advisory Board & Consultant | 6.9yrs | US$97.32k | sin datos |
4.0yrs
Permanencia media
66.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CTSO se considera experimentado (3.9 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 15.8yrs | US$1.33m | 1.36% $ 605.8k | |
| Co-Chairman of Cardiac Surgery Advisory Board & Consultant | 9.7yrs | US$97.32k | sin datos | |
| Member of Critical Care Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 9.5yrs | US$118.47k | 0.064% $ 28.3k | |
| Independent Director | 17.1yrs | US$101.93k | 0.036% $ 16.0k | |
| Member of Critical Care Advisory Board | no data | sin datos | sin datos | |
| Chairman of the Trauma Advisory Board | 11.1yrs | sin datos | sin datos | |
| Member of Trauma Advisory Board | no data | sin datos | sin datos | |
| Member of Trauma Advisory Board | 11.1yrs | sin datos | sin datos | |
| Chairman of Cardiac Surgery Advisory Board | 9.7yrs | sin datos | sin datos | |
| Member of Cardiac Surgery Advisory Board | 9.7yrs | sin datos | sin datos | |
| Independent Chairman of the Board | 8.8yrs | US$161.70k | 0.10% $ 46.0k |
9.7yrs
Permanencia media
62yo
Promedio de edad
Junta con experiencia: La junta directiva de CTSO se considera experimentada (9.6 años de antigüedad promedio).